US 2019/0194654 A1 · COMBINATION

Abstract

The present invention features methods of treating cancer with an immunomodulatory agent, such as an anti-PD-L1 antibody or an antigen-binding fragment thereof, and an antisense compound targeted to STAT3 in a subject in need thereof.

Claims21

Dependent claims

A method of treating cancer comprising administering:

(i) at least one immune checkpoint inhibitor;
and (ii) an antisense compound targeted to STAT3;
to a patient in need thereof.

Dependencies are inferred from the claim text.

Facts

Application

15/521,185Filed 20 Oct 2015

Priority

24 Oct 2014

Published

27 Jun 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C12N 15/111
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: general methods applicable to biologically…
A61K 38/1774
Receptors; Cell surface antigens; Cell surface determinants: immunoglobulin superfamily
A61P 35/00
Antineoplastic agents
C12N 15/113
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: non-coding nucleic acids modulating the…

Abstract

Claims21

Dependent claims

A method of treating cancer comprising administering:

(i) at least one immune checkpoint inhibitor;
and (ii) an antisense compound targeted to STAT3;
to a patient in need thereof.

Dependencies are inferred from the claim text.

Combination

Life of this patent

Abstract

Claims21

Combination

Life of this patent

Abstract

Claims21